A parallel phase I/II clinical trial design for combination therapies

Area of Science:

• Clinical Trials
• Biostatistics
• Pharmacology

Background:

• Combination therapies are increasingly used, especially in oncology.
• Traditional clinical trial designs are insufficient for evaluating multiple agents simultaneously.
• Specialized trial designs are needed for combination therapy evaluation.

Purpose of the Study:

• To propose a parallel phase I/II clinical trial design for evaluating combination therapies.
• To simultaneously assess safety and efficacy of combination dose levels.
• To select optimal combination doses efficiently.

Main Methods:

• A parallel phase I/II trial design with initial dose escalation.
• Adaptive randomization using Bayesian posterior probabilities to assign patients to effective doses.
• Elimination of doses with intolerable toxicity and closure of less effective doses.
• Trial stopping rules based on prespecified boundaries for safety, efficacy, or futility.

Main Results:

• The proposed design saves sample size compared to conventional designs.
• The parallel phase I/II trial demonstrates improved statistical power.
• The adaptive randomization efficiently allocates more patients to higher-efficacy doses.

Conclusions:

• The parallel phase I/II clinical trial design is an effective alternative for evaluating combination therapies.
• This adaptive approach optimizes patient allocation and resource utilization in clinical trials.
• The design shows promise for accelerating the development of effective combination treatments.